Korea's Ilyang Pharmaceutical Starts Phase III Trials For First-line CML Drug To Compete With Gleevec
This article was originally published in PharmAsia News
SEOUL - South Korea's Ilyang Pharmaceutical Co. Ltd. recently started Phase III trials for novel leukemia drug Supect (rodotinib) in Korea, India, Thailand, Philippines and Indonesia to determine whether it can gain approval in Korea as a first-line treatment for chronic myeloid leukemia and take on Novartis AG's Gleevec (imatinib). The company aspires to then bring the product to other Asian markets, and then eventually the U.S
You may also be interested in...
Ilyang gears up to launch its chronic myeloid leukemia drug in Korea and other Asian markets for second-line treatment. The drug could eventually compete with Novartis AG's Gleevec (imatinib), which is approved for first-line treatment.
SEOUL - South Korea's Ministry of Health and Welfare has selected 21 Korean pharmaceutical manufacturers and 17 medical equipment firms to support these companies in the development of globally competitive new drugs, marketing efforts and U.S. FDA approvals needed for their advancement into the U.S. market
SEOUL - OECD has recommended a set of changes - some of them already pursued by the South Korean government - to get South Korea's healthcare system working more efficiently to curtail rapid increases in healthcare spending